291 related articles for article (PubMed ID: 20814668)
1. Analysis and characterization of heparin impurities.
Beni S; Limtiaco JF; Larive CK
Anal Bioanal Chem; 2011 Jan; 399(2):527-39. PubMed ID: 20814668
[TBL] [Abstract][Full Text] [Related]
2. Electrophoresis for the analysis of heparin purity and quality.
Volpi N; Maccari F; Suwan J; Linhardt RJ
Electrophoresis; 2012 Jun; 33(11):1531-7. PubMed ID: 22736353
[TBL] [Abstract][Full Text] [Related]
3. Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples.
Alban S; Lühn S; Schiemann S; Beyer T; Norwig J; Schilling C; Rädler O; Wolf B; Matz M; Baumann K; Holzgrabe U
Anal Bioanal Chem; 2011 Jan; 399(2):605-20. PubMed ID: 20824424
[TBL] [Abstract][Full Text] [Related]
4. Characterization of currently marketed heparin products: key tests for quality assurance.
Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
[TBL] [Abstract][Full Text] [Related]
5. Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants.
Mendes A; Meneghetti MCZ; Palladino MV; Justo GZ; Sassaki GL; Fareed J; Lima MA; Nader HB
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426507
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
[TBL] [Abstract][Full Text] [Related]
7. Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE.
Zhang Z; Li B; Suwan J; Zhang F; Wang Z; Liu H; Mulloy B; Linhardt RJ
J Pharm Sci; 2009 Nov; 98(11):4017-26. PubMed ID: 19642166
[TBL] [Abstract][Full Text] [Related]
8. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
[TBL] [Abstract][Full Text] [Related]
9. Screening of heparin API by near infrared reflectance and Raman spectroscopy.
Spencer JA; Kauffman JF; Reepmeyer JC; Gryniewicz CM; Ye W; Toler DY; Buhse LF; Westenberger BJ
J Pharm Sci; 2009 Oct; 98(10):3540-7. PubMed ID: 19117047
[TBL] [Abstract][Full Text] [Related]
10. Orthogonal analytical approaches to detect potential contaminants in heparin.
Guerrini M; Zhang Z; Shriver Z; Naggi A; Masuko S; Langer R; Casu B; Linhardt RJ; Torri G; Sasisekharan R
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16956-61. PubMed ID: 19805108
[TBL] [Abstract][Full Text] [Related]
11. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
[TBL] [Abstract][Full Text] [Related]
12. One-hour screening of adulterated heparin by simplified peroxide digestion and fast RPIP-LC-MS(2).
Li H; Wickramasekara S; Nemes P
Anal Chem; 2015 Aug; 87(16):8424-32. PubMed ID: 26168275
[TBL] [Abstract][Full Text] [Related]
13. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.
Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U
Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266
[TBL] [Abstract][Full Text] [Related]
14. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
[TBL] [Abstract][Full Text] [Related]
15. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
[TBL] [Abstract][Full Text] [Related]
16. Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.
Volpi N; Maccari F; Linhardt RJ
Anal Biochem; 2009 May; 388(1):140-5. PubMed ID: 19232311
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of an ion-exchange chromatography method for heparin and its impurities in heparin products.
Thiangthum S; Vander Heyden Y; Buchberger W; Viaene J; Prutthiwanasan B; Suntornsuk L
J Sep Sci; 2014 Nov; 37(22):3195-204. PubMed ID: 25146711
[TBL] [Abstract][Full Text] [Related]
18. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
[TBL] [Abstract][Full Text] [Related]
19. (1)H NMR signal at 2.10 ppm in the spectrum of KMnO(4)-bleached heparin sodium: identification of the chemical origin using an NMR-only approach.
Kellenbach E; Sanders K; Michiels PJ; Girard FC
Anal Bioanal Chem; 2011 Jan; 399(2):621-8. PubMed ID: 21069304
[TBL] [Abstract][Full Text] [Related]
20. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
